Literature DB >> 6155582

Circulating immune complexes and thyroid-stimulating immunoglobulins before, during, and after antithyroid drug therapy in patients with Graves' disease.

D van der Heide, M R Daha, J H Bolk, J K Bussemaker, T W de Bruin, B M Goslings, L A van Es, A Querido.   

Abstract

Sera from patients with Graves' disease were assayed for thyroid-stimulating immunoglobulins (TSI) and circulating immune complexes (CIC) before, during, and after antithyroid drug treatment. 41 (72%) of 57 untreated patients had a positive TSI index and 17 (30%) had CIC. In untreated patients CIC were significantly more common in patients with a negative TSI index than in those with a positive one. It is suggested that because CIC prevent TSI from being detected the TSI index may be negative in Graves' disease. Early in the course of the treatment CIC developed in 85% of the patients; in all of these patients TSI disappeared. Later in the course of treatment when CIC could no longer be detected TSI did not reappear. These findings indicate that the development CIC could be the manifestation of the re-establishment of a natural tolerance to thyroid-stimulating hormone receptors in patients with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155582     DOI: 10.1016/s0140-6736(80)92652-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  Circulating immune complexes may play a regulatory and pathogenic role in experimental autoimmune uveoretinitis.

Authors:  E Kasp; M R Stanford; E Brown; A G Coombes; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

2.  [Determination of TSH receptor antibodies--clinical value].

Authors:  E Schifferdecker; F Schulz; K Schöffling
Journal:  Klin Wochenschr       Date:  1986-01-02

3.  Immunological aspects of Graves' disease patients in different clinical stages.

Authors:  A Gauna; G Segura; G Sartorio; R Soto; A Segal-Eiras
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

4.  10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAb).

Authors:  J Hensen; P Kotulla; R Finke; K Badenhoop; K Koppenhagen; H Meinhold; H Schleusener
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

5.  Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.

Authors:  J Charreire; G Karsenty; P Bouchard; G Schaison
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

6.  Graves' disease: immunological and immunogenetic indicators of relapse.

Authors:  T W de Bruin; J H Bolk; J K Bussemaker; T Stijnen; G M Schreuder; R R de Vries; D van der Heide
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-07

7.  [Diagnostic procedure in suspected functional disorders of the thyroid gland].

Authors:  R D Hesch
Journal:  Klin Wochenschr       Date:  1984-11-15

8.  Changes of circulating thyroid autoantibody levels during and after the therapy with methimazole in patients with Graves' disease.

Authors:  C Marcocci; L Chiovato; S Mariotti; A Pinchera
Journal:  J Endocrinol Invest       Date:  1982 Jan-Feb       Impact factor: 4.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.